Search Results for "Cleveland Heartlab Competitor"
Original Source: Cleveland HeartLab LLC
Cleveland HeartLab LLC is a specialty clinical laboratory and disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers. CHL operates a CLIA-certified and CAP-accredited clinical laboratory located on the main campus of the Cleveland Clinic. The company has developed a panel of tests that physicians use in the management and reduction of inflammation in their patients. CHL runs a research &...
Matching Channels
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection. CMV is the most common opportunistic infection after solid organ transplantation. The incidence...
Aorfix™ endovascular stent graft – Treating the cases other grafts cannot treat Aorfix™ is the only endovascular stent graft licensed in Europe to treat aneurysms in complex anat...
Insulin like Growth Factor 1 Receptor IGF 1R
Although the insulin-like growth factor-1 receptor (IGF-1R) was first cloned in 1986, it was the success of targeted drugs such as trastuzumab and imatinib that tyrosine kinase inhibitors and growth...
Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...
Staphylococcal aureus infections
Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently...
Matching News
Cleveland HeartLab raises $14.7M for heart inflammation test
Cleveland HeartLab has obtained $14.7 million in an equity funding round led by Mutual Capital Partners. -More-
Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced three additions to its team th...
Cleveland HeartLab to Host Annual Symposium on Cardiovascular Disease, Wellness
Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its annual symposium, Whe...
Cleveland HeartLab Honored with Prestigious 2013 NorTech Innovation Award
Cleveland HeartLab announced today that the company was recognized as a recipient of the 2013 NorTech Innovation Awards. The award was received yesterday by Cleveland HeartLab, Pr...
Cleveland HeartLab (CHL), an advanced clinical laboratory focused on heart inflammation testing, is going on the road to provide the company’s innovative “IT” inflamm...
[Cleveland Heart] brings in $30mm through early venture round
Cardiovascular device firm [Cleveland Heart Inc.] has raised $30mm in an early venture round. Korean PE firm Power Heart Consortium supplied the funds. Formed in 2007 and spun off from the [Clevelan...
Cleveland Clinic researcher identifies 2 new genetic mutations associated with Cowden syndrome
(Cleveland Clinic) Cleveland Clinic researchers from the Lerner Research Institute have uncovered two new genes associated with Cowden syndrome according to a new study, published today in the online...
Cleveland LASIK and Cataract Surgeon Dr Michael Rom Speaks in Israel
Cleveland, OH (PRWEB) May 02, 2013 A very unique opportunity was presented this year to Cleveland ophthalmologist, Michael Rom, M.D. In January, Dr. Rom was invited to speak to almost 250 fellow...
Matching PubMed Articles
The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease.
A 12-Year Perspective on the World's First Total Laryngeal Transplant.
Description of two new MICA alleles: MICA*058 and MICA*002:03.
We describe two novel alleles, MICA*058 and MICA* 002:03.
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
